Key result
Chronic oral anticoagulation was associated with a lower incidence of diagnosed prostate cancer (IRR 0.70; 95% CI 0.62-0.80), an apparent protective effect likely resulting from detection bias.
Why the study?
Warfarin treatment has been associated with lower prostate cancer risk without a known mechanism, leading to the hypothesis that reluctance to perform biopsies in anticoagulated men causes detection bias.
Does chronic oral anticoagulation reduce the incidence of diagnosed prostate cancer in elderly men compared to the general population?
Cohort (n=374,115)
Does chronic oral anticoagulation reduce the incidence of diagnosed prostate cancer in elderly men compared to the general population?
The previously reported protective effect of warfarin against prostate cancer is likely an artifact of detection bias due to lower rates of prostate biopsies in anticoagulated men.
May reflect detection bias from fewer biopsies rather than true protection; leaves open whether any biological effect exists.
Warfarin treatment has been associated with lower risks of prostate cancer, without a specified biological mechanism. Our study tested the hypothesis that reluctance to perform prostate biopsies in men who are anticoagulated results in lower rates of diagnosed prostate cancer, leading to an apparent protective effect. Rates of prostate biopsies have decreased from 2000 to 2015, allowing calendar time to be used as the intervention. In a national population-based sample of elderly men, our study compared trends in prostate cancer incidence between 17,815 men treated with chronic oral anticoagulation for prosthetic heart valve thromboprophylaxis and a general population comparison group of 356,300 men. Cancer events were based on administrative claims. Among men enrolled in 2000-2001 and followed through 2015, prostate cancer incidence was substantially lower in the anticoagulation group (adjusted incidence rate ratio [IRR] 0.70; 95% confidence interval [CI] 0.62-0.80). Incidence decreased over time in the general population group to approach that of the anticoagulation group among men enrolled in 2008-2010 (IRR 0.86; 95% CI 0.71-1.04). Rates of prostate biopsies also decreased over time in the general population group to match the rate in the anticoagulation group. These results indicate that the apparent protective effect of warfarin treatment on the risk of prostate cancer is likely the result of detection bias from lower rates of biopsies among men who are anticoagulated.
No takes yet. Share an insight, caveat, or question.
Michael M. Ward (2019) conducted a cohort in Prostate cancer (n=374,115). Chronic oral anticoagulation vs. General population was evaluated on Prostate cancer incidence (IRR 0.70, 95% CI 0.62-0.80). Chronic oral anticoagulation was associated with a lower incidence of diagnosed prostate cancer (IRR 0.70; 95% CI 0.62-0.80), an apparent protective effect likely resulting from detection bias.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: